SCHEMBL17634211

SCHEMBL17634211

O=C1Nc2ccccc2SC1c1ccc(C(F)(F)F)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.46
TP53 P04637 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
HSD17B10 Q99714 3/20 0.41
USP2 O75604 2/20 0.41
KDM4E B2RXH2 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
ESR1 P03372 1/20 0.41
POLB P06746 1/20 0.41
THRB P10828 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
PTPN7 P35236 1/20 0.41
RECQL P46063 1/20 0.41
ESR2 Q92731 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
GAA P10253 2/20 0.40
MAPK1 P28482 1/20 0.40
HDAC4 P56524 1/20 0.39
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17634130 0.80 MAPT (0.66) MAPTTP53SMN1; SMN2HSD17B10USP2
SCHEMBL7278586 0.76 MAPT (0.62) MAPTTP53SMN1; SMN2HSD17B10USP2
SCHEMBL3626456 0.75 CA2 (0.62) MAPTTP53SMN1; SMN2HSD17B10USP2
SCHEMBL17634224 0.74 HDAC4 (0.38) MAPTTP53SMN1; SMN2HSD17B10USP2
Hydrochloric Acid SCHEMBL10770897 0.73 CA2 (0.61) MAPTTP53SMN1; SMN2HSD17B10USP2
SCHEMBL7281597 0.73 HSD17B10 (0.52) MAPTTP53SMN1; SMN2HSD17B10USP2
SCHEMBL10650323 0.73 HSD17B10 (0.49) MAPTTP53SMN1; SMN2HSD17B10USP2
SCHEMBL2362237 0.73 HSD17B10 (0.49) MAPTTP53SMN1; SMN2HSD17B10USP2
SCHEMBL10653449 0.67 HSD17B10 (0.49) MAPTTP53SMN1; SMN2HSD17B10USP2
SCHEMBL9876505 0.66 HSD17B10 (0.73) MAPTTP53SMN1; SMN2HSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197900-B1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME (US) 2020-02-12 EP disclosed
US-9969752-B2 Inhibitors of HIF prolyl hydroxylase MERCK SHARP & DOHME CORP. (US) 2018-05-15 US disclosed
US-20170233412-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2017-08-17 US disclosed
EP-3197900-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE Merck Sharp & Dohme Corp. (US) 2017-08-02 EP disclosed
WO-2016049099-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2016-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233412-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE HIF1AN, HIF1A, EGLN2 MAPT 3798/4885TP53 2925/4885SMN1; SMN2 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.